Thymulin for Health & Longevity - Quick Reference Sheet

Thymulin for Health & Longevity

Created on 07/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Thymulin is a zinc-dependent thymus hormone that helps immune T-cells mature, and its activity falls sharply with age. Its best-supported use today is as a marker of zinc status and reversible immune aging. Benefits beyond that rest almost entirely on animal studies, and its safety in people is untested. (Full Review)

Protocol

Dose
10–20 mcg daily
Subcutaneous injection; practitioner protocols, not trial-validated
Course
4–12 weeks
Short, repeatable cycles rather than continuous use
Timing
Evening
Aligns with circadian thymic secretion; once-daily standard
Time to effect
Immune & biomarker changes
Weeks to ~2 months
Seen via zinc-driven restoration; direct-injection timelines not established

Benefits

Contraindications
  • Active autoimmune disease
  • Immunosuppressive therapy (e.g., post-transplant)
  • History of thymoma or thymic malignancy
  • Pregnancy or breastfeeding
  • Children and adolescents
Key Interactions
  • Immunosuppressants (corticosteroids, calcineurin inhibitors such as tacrolimus and cyclosporine, biologics)
  • Zinc (required for activity)
  • Copper (high zinc can induce deficiency)
  • Arginine and melatonin (additive/enabling)
  • Growth hormone and thyroid hormone

Risk & Side Effects

  • High:
  • Medium:
  • Low: Injection-site reactions; immune overmodulation / autoimmune concern
  • Speculative: Neuroendocrine and reproductive effects; unknown long-term and immunogenicity risks; product quality and contamination risk

Monitoring

Marker Target Why
Serum/plasma zinc ~90–110 mcg/dL Enables thymulin activity; deficiency inactivates the hormone
Active/total thymulin ratio Higher ratio = better activity Direct readout of biologically active hormone and zinc bioavailability
Serum copper ~90–120 mcg/dL Guards against copper depletion from chronic zinc supplementation
hs-CRP <1.0 mg/L Tracks systemic inflammation that suppresses thymic function
IL-6 (interleukin-6) Low-normal per assay High IL-6 drives thymic involution and lowers zinc bioavailability
CBC with lymphocyte subsets Age-appropriate normal; adequate T-cell counts Reflects downstream immune capacity thymulin aims to support

Cadence: Reassess zinc and inflammatory markers ~4–8 weeks after a change, then every 3–6 months; check copper every 6–12 months if zinc is supplemented chronically.

Qualitative Assessment

  • Frequency and duration of common infections (e.g., colds) over a season
  • Subjective energy and recovery
  • General resilience and wound healing
  • Absence of new adverse effects (injection-site or systemic)